The latest price target for GoodRx Holdings (NASDAQ:GDRX) was reported by Barclays on December 9, 2025. The analyst firm set a price target for $3.00 expecting GDRX to rise to within 12 months (a possible 8.89% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for GoodRx Holdings (NASDAQ:GDRX) was provided by Barclays, and GoodRx Holdings initiated their underweight rating.

The last upgrade for GoodRx Holdings Inc happened on May 23, 2024 when RBC Capital raised their price target to $10. RBC Capital previously had a sector perform for GoodRx Holdings Inc.

The last downgrade for GoodRx Holdings Inc happened on January 2, 2024 when B of A Securities changed their price target from $8 to $4.5 for GoodRx Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GoodRx Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GoodRx Holdings was filed on December 9, 2025 so you should expect the next rating to be made available sometime around December 9, 2026.

While ratings are subjective and will change, the latest GoodRx Holdings (GDRX) rating was a initiated with a price target of $0.00 to $3.00. The current price GoodRx Holdings (GDRX) is trading at is $2.76, which is within the analyst’s predicted range.